Mirtazapine Tablets — Class II drug recall D-0493-2017
Terminated recall by Mylan Institutional, Inc. (d.b.a. UDL Laboratories), reported 2017-03-15, distributed nationwide. Presence of Foreign Tablets/Capsules; possibility of Glipizide 10 mg tablets commingled
| Recall number | D-0493-2017 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Mylan Institutional, Inc. (d.b.a. UDL Laboratories), Rockford, IL, United States |
| Recall initiated | 2017-01-27 |
| Classified | 2017-03-08 |
| Reported by FDA | 2017-03-15 |
| Terminated | 2019-03-15 |
| Distributed | Nationwide (US) |
| NDC | 51079-0086, 51079-0086-01, 51079-0086-20, 51079-0087, 51079-0087-01, 51079-0087-20, 51079-0088, 51079-0088-01, 51079-0088-20 |
| Lot numbers | 3083289 |
| Expiration dates | 2018-12 |
Product
Mirtazapine Tablets, USP, 45 mg. Rx only, 100 Tablets (10 X 10). Manufactured by: Mylan Pharmaceuticals Inc, Morgantown, WV ---NDC 51079-088-20
Reason for recall
Presence of Foreign Tablets/Capsules; possibility of Glipizide 10 mg tablets commingled
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0493-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.